Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Altera

Administered By

Awarded By

Contributors

Start/End

  • July 14, 2020 - April 30, 2023